Navigation Links
Senetek PLC Announces New Investor Communication Hotline

NAPA, Calif., April 1 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced plans for the creation of a new communication hotline for the expressed purpose of keeping the investment community updated on key events. Bi-weekly updates will be recorded on a designated call-in number which is targeted to be up and running in early May. In addition, callers will be able to leave their contact information regarding any questions they may have.

The Company will periodically supplement the hotline with live investor teleconferences to announce and discuss significant material events. Frank J. Massino, Chairman and Chief Executive Officer stated, "that in today's volatile business and political environments, it is important to keep our shareholders updated in a timely manner on events shaping the Company."

About Senetek PLC:

Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites:

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Announces 2008 Annual General Meeting Voting Results
2. Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
3. Senetek Affirms Strong Financial Position
4. Senetek PLC Reports Second Quarter 2008 Financial Results
5. Senetek PLC Reports First Quarter 2008 Financial Results
6. Senetek PLC Announces Appointments of Key Personnel
7. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
8. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
9. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
10. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
11. ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... 2016 adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):